IKT vs LCID · $215.2M cap vs rev $687.8M
Inhibikase Therapeutics Inc (IKT) versus Lucid Group Inc (LCID) — a side-by-side from cached financials, not a winner call.
Inhibikase Therapeutics Inc (IKT) is a biotechnology company listed on US.
Lucid Group Inc (LCID) is a auto manufacturers company listed on NASDAQ. It is led by Silvio Napoli.
Latest reported IKT revenue for 2026-06-30 was $0. Net income was -$36.0M. IKT currently screens at market cap $215.2M.
Latest reported LCID revenue for 2026-06-30 was $687.8M. Net income was -$2.06B. LCID currently screens at market cap $2.04B.
IKT currently screens at market cap $215.2M. LCID currently screens at market cap $2.04B.
Not investment advice. Open the IKT and LCID stock pages for the full models.
Not investment advice.